Moderate Risk QTc-Prolonging Agents

All categories
DBCAT002690Pharmacologic class

Drugs that have demonstrated moderate QTc interval prolongation in either animal or human studies. A DrugBank category of 122 drugs. 97 of them are approved.

Part of
QTc Prolonging Agents
Also known as
Moderate Risk QT-Prolonging Agents · Moderate Risk QT Prolonging Agents · Moderate Risk QTc Prolonging Agents
Drugs

and 97 more with a free account

What you can answer from here — as of January 11, 2019

122DrugsEach linked to its full drug card
Sign in
287Drug targetsEvery drug–target pair in the class, with bond type
Sign in
35,109Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
29Routes of administrationHow the drugs in this class are given
Sign in

Which targets do Moderate Risk QTc-Prolonging Agents share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In